Prescription drug costs are expected to see the fastest annual growth among health care expenditures over the next decade, the Centers for Medicare and Medicaid Services (CMS) predicts, rising an average of 6.3% a year due to higher drug prices and more use of specialty drugs such as those for genetic disorders and cancer.
Overall, CMS projects that U.S. health spending will rise 5.3% in 2018, reflecting rising prices of medical goods and services and higher Medicaid costs. The agency forecasts the upward trend will last for the next decade, Reuters reports.
The increase represents a sharp uptick from 2017 spending, which the CMS now estimates to have been a 4.6% climb to nearly $3.5 trillion. It had previously forecast a 2017 rise of 5.4%. The primary drivers of the increased spending include the aging baby-boom population that will increase enrollment in the Medicare health insurance program for the elderly and disabled, a climb in the prices of medical goods and services, and more disposable personal income, the report said.
CMS projected that health care spending will on average rise 5.5% annually from 2017 to 2026 and will comprise 19.7% of the U.S. economy in 2026, up from 17.9% in 2016, Reuters reported. By 2026, health spending is projected to reach $5.7 trillion.
Acceleration in prescription drug price growth (4.4% in 2018 from 2.1% in 2017) reflects the expectation that brand-name drug prices will more strongly influence growth in that year because the dollar value of drugs losing patents in 2018 is smaller than in prior years, the CMS said.
Besides prescription drugs, higher spending in Medicare and Medicaid, the government health insurance program for the poor and disabled, is also expected to contribute significantly to rising health spending as the population ages and relies more heavily on health care services.
The report also projected a slightly higher share of the population will be uninsured in 2026. The insured rate is forecast to drop to 89.3% from 91.1% in 2016 after Republicans last year upended Obamacare’s individual mandate, the requirement that most Americans purchase health insurance or else pay a fine, as part of a larger overhaul of the U.S. tax code.
Spending for 2017 rose faster than in 2016, when it rose 4.3%. The report cited higher Medicare spending, rising prices for health care goods and services, and increases in premiums for health insurance purchased through the Obamacare individual market.
Republicans last year repeatedly failed to repeal and replace Obamacare, a top campaign promise of President Donald Trump. Instead, the Trump administration has weakened the law through a series of regulatory actions and rules, causing a rise in premiums in the individual markets created under the Affordable Care Act.
Paul Lendner ist ein praktizierender Experte im Bereich Gesundheit, Medizin und Fitness. Er schreibt bereits seit über 5 Jahren für das Managed Care Mag. Mit seinen Artikeln, die einen einzigartigen Expertenstatus nachweißen, liefert er unseren Lesern nicht nur Mehrwert, sondern auch Hilfestellung bei ihren Problemen.